Skip to main content

Movers & Shakers: Jul 29, 2011

Premium

Proteome Sciences has appointed Glenn Barney vice president of business development in North America.

Previously, Barney was VP of business development for NextGen Sciences. He has also held senior positions at Decision Biomarkers and PerkinElmer.


Dario Alessi has been appointed director of the Medical Research Council's Protein Phosphorylation Unit at the University of Dundee, a research group dedicated to the study of protein phosphorylation.

Alessi is currently deputy director of the unit as well as a professor of signal transduction in the College of Life Sciences at the University of Dundee. In 2005 he was awarded the EMBO Gold Medal, a research prize for life scientists under the age of 40, and was elected a fellow of the Royal Society in 2008.

Alessi will succeed the current director Philip Cohen, who will step down in April 2012.


BG Medicine has appointed former BioMérieux CEO Stephane Bancel to serve as chairman of its board of directors.

Bancel will replace Noubar Afeyan, a company founder and chairman of the board since the company's inception as well as CEO and managing partner of Flagship Ventures. Afeyan will continue to serve on the firm's board.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.